{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:42:58Z","timestamp":1786736578958,"version":"build-2736575974"},"reference-count":57,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Afr Med"],"published-print":{"date-parts":[[2020]]},"DOI":"10.4103\/aam.aam_24_19","type":"journal-article","created":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T01:51:13Z","timestamp":1584064273000},"page":"1","source":"Crossref","is-referenced-by-count":7,"title":["Cytotoxic-induced heart failure among breast cancer patients in Nigeria: A call to prevent today's cancer patients from being tomorrow's cardiac patients"],"prefix":"10.4103","volume":"19","author":[{"given":"Raphael","family":"Anakwue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/1596-3519.280495-1","first-page":"115","volume-title":"Assessment of anthracycline-induced cardiotoxicity with electrocardiography","author":"Horacek","year":"2009","journal-title":"Exp Oncol"},{"key":"key-10.4103\/1596-3519.280495-2","first-page":"179","volume-title":"Breast cancer in Nigeria","author":"Adebamowo","year":"2000","journal-title":"West Afr J Med"},{"key":"key-10.4103\/1596-3519.280495-3","unstructured":"World Health Organization. WHO Model List of Essential Medicines. 2015 edition. World Health Organization; 2015."},{"key":"key-10.4103\/1596-3519.280495-4","first-page":"120","volume-title":"Breast cancer in Eastern Nigeria: A ten year review","author":"Anyanwu","year":"2000","journal-title":"West Afr J Med"},{"key":"key-10.4103\/1596-3519.280495-5","first-page":"284","volume-title":"Breast cancer burden in Maiduguri, North Eastern Nigeria","author":"Nggada","year":"2008","journal-title":"Breast J"},{"key":"key-10.4103\/1596-3519.280495-6","first-page":"362","volume-title":"Elevated B-type natriuretic peptide levels after anthracycline administration","author":"Suzuki","year":"1998","journal-title":"Am Heart J"},{"key":"key-10.4103\/1596-3519.280495-7","first-page":"267","volume-title":"Cancer genetics and the cardiotoxicity of the therapeutics","author":"Lal","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"key-10.4103\/1596-3519.280495-8","first-page":"5296","volume-title":"Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer","author":"Du","year":"2009","journal-title":"Cancer"},{"key":"key-10.4103\/1596-3519.280495-9","first-page":"1293","volume-title":"Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: A retrospective cohort study","author":"Bowles","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"key-10.4103\/1596-3519.280495-10","first-page":"1215","volume-title":"Cardiac dysfunction in the trastuzumab clinical trials experience","author":"Seidman","year":"2002","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1596-3519.280495-11","first-page":"e000665","volume-title":"Cancer therapy-induced cardiotoxicity: Basic mechanisms and potential cardioprotective therapies","author":"Hahn","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"key-10.4103\/1596-3519.280495-12","first-page":"710","volume-title":", Von Hoff AL, Rozencweig M, et al. Risk factors for doxorubicin-induced congestive heart failure","author":"Von","year":"1979","journal-title":"Ann Intern Med"},{"key":"key-10.4103\/1596-3519.280495-13","first-page":"688","volume-title":"Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: Systematic review of the literature and recommendations for use","author":"Dolci","year":"2008","journal-title":"Am J Clin Pathol"},{"key":"key-10.4103\/1596-3519.280495-14","first-page":"263","volume-title":"Cardiotoxicity of chemotherapeutic agents: Incidence, treatment and prevention","author":"Pai","year":"2000","journal-title":"Drug Saf"},{"key":"key-10.4103\/1596-3519.280495-15","first-page":"1102","volume-title":"Cancer drugs and the heart: Importance and management","author":"Suter","year":"2013","journal-title":"Eur Heart J"},{"key":"key-10.4103\/1596-3519.280495-16","unstructured":"National Cancer Institute. Cancer Therapy Evaluation Program. Available from: http:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcv20_4e30e992.pdf. [Last accessed on 2019 Jun]."},{"key":"key-10.4103\/1596-3519.280495-17","first-page":"14","volume-title":"Cardiac toxicity in breast cancer survivors: Review of potential cardiac problems","author":"Bird","year":"2008","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/1596-3519.280495-18","first-page":"99","volume-title":"Heart success program.An interdisciplinary patient-centered approach to cancer patients with heart failure","author":"Fadol","year":"2015","journal-title":"Prog Pediatr Cardiol"},{"key":"key-10.4103\/1596-3519.280495-19","unstructured":"Yeh ET, editor. MD Anderson Practices in Onco-Cardiology. Texas: Primedia E-launch LLC; 2016."},{"key":"key-10.4103\/1596-3519.280495-20","first-page":"893","volume-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American society of clinical oncology clinical practice guideline","author":"Armenian","year":"2017","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1596-3519.280495-21","first-page":"1","volume-title":"Cardiovascular side effects of cancer therapies: A position statement from the heart failure association of the European Society of Cardiology","author":"Eschenhagen","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"key-10.4103\/1596-3519.280495-22","first-page":"2129","volume-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the heart failure association (HFA) of the ESC","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"key-10.4103\/1596-3519.280495-23","first-page":"509","volume-title":"Time trends of left ventricular ejection fraction and Myocardial deformation indices in a cohort of Women with breast cancer treated with anthracyclines, taxanes, and trastuzumab","author":"Tan","year":"2015","journal-title":"J Am Soc Echocardiogr"},{"key":"key-10.4103\/1596-3519.280495-24","first-page":"531","volume-title":"Utility of 3-dimensional echocardiography, global longitudinal strain, and exercise stress echocardiography to detect cardiac dysfunction in breast cancer patients treated with doxorubicin-containing adjuvant therapy","author":"Khouri","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"key-10.4103\/1596-3519.280495-25","first-page":"1375","volume-title":"Early detection and prediction of cardiotoxicity in chemotherapy-treated patients","author":"Sawaya","year":"2011","journal-title":"Am J Cardiol"},{"key":"key-10.4103\/1596-3519.280495-26","first-page":"945","volume-title":"Two-dimensional myocardial strain imaging detects changes in left ventricular systolic function immediately after anthracycline chemotherapy","author":"Stoodley","year":"2011","journal-title":"Eur J Echocardiogr"},{"key":"key-10.4103\/1596-3519.280495-27","first-page":"3396","volume-title":"Left ventricular systolic function in HER2\/neu negative breast cancer patients treated with anthracycline chemotherapy: A comparative analysis of left ventricular ejection fraction and myocardial strain imaging over 12 months","author":"Stoodley","year":"2013","journal-title":"Eur J Cancer"},{"key":"key-10.4103\/1596-3519.280495-28","first-page":"517","volume-title":"Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy","author":"Cardinale","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"key-10.4103\/1596-3519.280495-29","first-page":"710","volume-title":"Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy","author":"Cardinale","year":"2002","journal-title":"Ann Oncol"},{"key":"key-10.4103\/1596-3519.280495-30","first-page":"2749","volume-title":"Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy","author":"Cardinale","year":"2004","journal-title":"Circulation"},{"key":"key-10.4103\/1596-3519.280495-31","first-page":"567","volume-title":"Drug-induced cardiotoxicity studied by longitudinal B-type natriuretic peptide assays and radionuclide ventriculography","author":"Pichon","year":"2005","journal-title":"In Vivo"},{"key":"key-10.4103\/1596-3519.280495-32","first-page":"1405","volume-title":"N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: A marker predictive of cardiac dysfunction?","author":"Sandri","year":"2005","journal-title":"Clin Chem"},{"key":"key-10.4103\/1596-3519.280495-33","first-page":"72","volume-title":"Epidemiology of anthracycline cardiotoxicity in children and adults","author":"Grenier","year":"1998","journal-title":"Semin Oncol"},{"key":"key-10.4103\/1596-3519.280495-34","first-page":"196","volume-title":"Doxorubicin cardiotoxicity in African Americans","author":"Hasan","year":"2004","journal-title":"J Natl Med Assoc"},{"key":"key-10.4103\/1596-3519.280495-35","doi-asserted-by":"crossref","unstructured":"Launchbury AP, Habboubi N. Epirubicin and doxorubicin: A comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat Rev 1993;19:197-228.","DOI":"10.1016\/0305-7372(93)90036-Q"},{"key":"key-10.4103\/1596-3519.280495-36","first-page":"63","volume-title":"Anthracycline chemotherapy and cardiotoxicity","author":"McGowan","year":"2017","journal-title":"Cardiovasc Drugs Ther"},{"key":"key-10.4103\/1596-3519.280495-37","doi-asserted-by":"crossref","unstructured":"Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer 2003;97:2869-79.","DOI":"10.1002\/cncr.11407"},{"key":"key-10.4103\/1596-3519.280495-38","first-page":"1114","volume-title":"Cyclophosphamide cardiotoxicity: An analysis of dosing as a risk factor","author":"Goldberg","year":"1986","journal-title":"Blood"},{"key":"key-10.4103\/1596-3519.280495-39","first-page":"505","volume-title":"Cardiac toxicity of 5-fluorouracil: A study on 1083 patients","author":"Labianca","year":"1982","journal-title":"Tumori"},{"key":"key-10.4103\/1596-3519.280495-40","first-page":"1","volume-title":"Cardiotoxicity of 5-fluorouracil","author":"Alter","year":"2006","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"key-10.4103\/1596-3519.280495-41","first-page":"1318","volume-title":"Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer","author":"Swain","year":"1997","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/1596-3519.280495-42","first-page":"159","volume-title":"Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity","author":"Oliveira","year":"2004","journal-title":"Toxicol Appl Pharmacol"},{"key":"key-10.4103\/1596-3519.280495-43","first-page":"2258","volume-title":"Protective effects of carvedilol against anthracycline-induced cardiomyopathy","author":"Kalay","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"key-10.4103\/1596-3519.280495-44","first-page":"2474","volume-title":"Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition","author":"Cardinale","year":"2006","journal-title":"Circulation"},{"key":"key-10.4103\/1596-3519.280495-45","first-page":"47","volume-title":"Carvedilol administration can prevent doxorubicin-induced cardiotoxicity: A double-blind randomized trial","author":"Tashakori","year":"2016","journal-title":"Cardiology"},{"key":"key-10.4103\/1596-3519.280495-46","first-page":"1671","volume-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): A 2\u00d72 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","author":"Gulati","year":"2016","journal-title":"Eur Heart J"},{"key":"key-10.4103\/1596-3519.280495-47","first-page":"298","volume-title":"Biological correlates of acute hypersensitivity events with DAB (389) IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: Decreased frequency and severity with steroid premedication","author":"Foss","year":"2001","journal-title":"Clin Lymphoma"},{"key":"key-10.4103\/1596-3519.280495-48","first-page":"127","volume-title":"Cardiovascular status of patients after chemotherapy for haematological cancers in Jos Nigeria","author":"Okeahialam","year":"2017","journal-title":"J Cancer Clin Trials"},{"key":"key-10.4103\/1596-3519.280495-49","first-page":"6","volume-title":"Cardiovascular disease mortality among breast cancer survivors","author":"Bradshaw","year":"2016","journal-title":"Epidemiology"},{"key":"key-10.4103\/1596-3519.280495-50","first-page":"1981","volume-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"key":"key-10.4103\/1596-3519.280495-51","first-page":"186","volume-title":"Strategies to prevent and treat cardiovascular risk in cancer patients","author":"Cardinale","year":"2013","journal-title":"Semin Oncol"},{"key":"key-10.4103\/1596-3519.280495-52","first-page":"213","volume-title":"Anthracycline-induced cardiomyopathy: Clinical relevance and response to pharmacologic therapy","author":"Cardinale","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"key-10.4103\/1596-3519.280495-53","unstructured":"Fadol A. Heart Success for Cancer Patients. Houston, Texas: MD Anderson Cancer Center; 2014."},{"key":"key-10.4103\/1596-3519.280495-54","first-page":"887","volume-title":"A new frontier: Cardio-oncology","author":"Cardinale","year":"1996","journal-title":"Cardiologia"},{"key":"key-10.4103\/1596-3519.280495-55","first-page":"35","volume-title":"Cardiac toxicity: Old and new issues in anti-cancer drugs","author":"Sereno","year":"2008","journal-title":"Clin Transl Oncol"},{"key":"key-10.4103\/1596-3519.280495-56","first-page":"2231","volume-title":"Cardiovascular complications of cancer therapy: Incidence, pathogenesis, diagnosis, and management","author":"Yeh","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"key-10.4103\/1596-3519.280495-57","first-page":"14","volume-title":"Cardiotoxicity of anticancer drugs: The need for cardio-oncology and cardio-oncological prevention","author":"Albini","year":"2010","journal-title":"J Natl Cancer Inst"}],"container-title":["Annals of African Medicine"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:43:37Z","timestamp":1786733017000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aam.aam_24_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"alternative-id":["280495"],"URL":"https:\/\/doi.org\/10.4103\/aam.aam_24_19","relation":{},"ISSN":["1596-3519"],"issn-type":[{"value":"1596-3519","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}